Aap Implantate Ag · XETR:AAQ1
Aap Implantate — Frühjahrskonferenz 2019
20 slides from Aap Implantate's conference presentation, May 14, 2019
Slide 1: aap Implantate AG Corporate Presentation
aap Implantate AG Corporate Presentation Frühjahrskonferenz 2019 Rubino Di Girolamo, CEO Making Trauma Treatment Marek Hahn, CFO Better and Cost-Effective Frankfurt am Main, May 14, 2019
Slide 2: Safe Harbor Statement
Safe Harbor Statement Our publication may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual
Slide 3: Investment Highlights
Investment Highlights aap is a German-based medtech company, a pure player in trauma with exciting and 1 IP-protected platform technologies addressing unmet needs in orthopedics aap is a front runner in antibacterial silver coating technology for implantable medical 2 devices which reduces surgical
Slide 4: aap at a Glance
aap at a Glance Pure player in trauma Organisation Technologies ➢ Globally operating medical device company based in Germany ➢ Founded in 1990 Antibacterial Resorbable ➢ 148 Employees (31/12/2018) Silver Coating Magnesium Three innovative and IP- ➢ Distribution: Implants protected platform • Germany
Slide 5: Where are we today?
Where are we today? ➢ Since 2017 after diverse strategic divestitures a pure player in trauma with the mission to make trauma treatment better for doctors and patients and cost effective through incremental and breakthrough innovations FOCUSED ON TRAUMA ➢ Unique and innovative technology and product
Slide 6: Platform Technology – LOQTEQ
Platform Technology – LOQTEQ ➢ LOQTEQ® System (clinically proven and rolled-out in key markets) ➢ Comprehensive trauma product portfolio with more than 90% indication coverage ➢ Strong IP protection ➢ Products providing clinical as well as economical competitive advantages compared to global leaders
Slide 7: Value Creation
Value Creation Approach to exploit the market with Approach Successes Future Growth ➢ Direct sales force to ➢ Comprehensive portfolio (>90% ➢ Increase of market hospitals, buying indication coverage) enabled presence with >20% syndicates, and hospital listing at major hospital groups sales growth pe
Slide 8: Platform Technology – Silver Coating
Platform Technology – Silver Coating ➢ Silver Coating Technology (game changer technology) ➢ Front runner in developing antibacterial silver coating technology for implantable medical devices ➢ Technology and product development accomplished ➢ Final stage to start human clinical study in Germany / U
Slide 9: Value Creation
Value Creation Approach to exploit the market with Silver Coating Approach Successes Future Value Creation ➢ Own distribution and ➢ Application for approval ➢ Distribution of silver coated partnerships with of human clinical study aap products global companies submitted to BfArM ➢ Co-development and
Slide 10: Platform Technology – Magnesium Implants
Platform Technology – Magnesium Implants ➢ Coated Resorbable Magnesium Implant Technology (open for co-investment) ➢ Avoids second surgery for implant removal thanks to resorption of the implant in the body after fracture healing ➢ Technology and products under development ➢ First animal studies acc
Slide 11: Value Creation
Value Creation Approach to exploit the market with Magnesium Implants Approach Successes Future Value Creation ➢ Joint development ➢ Unique magnesium alloy ➢ Joint development and and distribution with with good biomechanical distribution agreement co-investor properties combined with with co-invest
Slide 12: Value Creation – Sum of the Parts
Value Creation Sum of the Parts - Strategic framework ➢ Potential to be first mover in trauma application ➢ Wide range of applications outside trauma (i.e. cardiology) ➢ Increasing interest by global companies ➢ Valuation: Assessment by PWC on licensing opportunities shows big value potential ➢ Lead
Slide 13: The Way Ahead
The Way Ahead Key success factors 2019 and ahead ➢ Accelerated Top-line growth via: ➢ Increase in domestic and international sales as a result of efforts made in 2018 ➢ Establish new US team with focus on listing at national contracts and active training of clients ➢ Selected distribution partnershi
Slide 14: Many thanks for your attention!
Many thanks for your attention! Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app:
Slide 15: Appendix
Appendix qos
Slide 16: Update Q1/2019
Update Q1/2019 ➢ Q1/2019 Key Results ➢ Good start to 2019 with significant sales growth (+26% yoy to EUR 3.5 million) and substantially improved EBITDA (+37% to EUR -1.0 million); sales and EBITDA above the guidance ➢ Double-digit sales growth rates in all regions: ➢ Measures to strengthen financial
Slide 17: aap by numbers
aap by numbers Overview P & L (in EUR million) FY/2018 FY/2017 Sales 10.8 10.9 EBITDA -6.4 -6.2 Capital Structure (in EUR million) 31/12/2018 31/12/2017 Total Assets 42.2 50.5 Equity Ratio 83% 84% Cash Structure (in EUR million) 31/12/2018 31/12/2017 Cash (per B/S) 4.3 13.3 Net Cash (per B/S) 4.0 12
Slide 18: aap by numbers – Closer look at sales
aap by numbers Closer look at sales Sales (in EUR million) FY/2018 FY/2017 Change Trauma 10,816 10,648 +2% Germany 2,774 2,427 +14% North America 2,240 3,071 -27% North America Distributors 2,172 2,491 -13% North America Global Partners 68 580 -88% International (without North America) 5,802 5,150 +
Slide 19: Notes
Notes cap
Slide 20: Investor Relations contact
Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app: